Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer.

[1]  F. Saad,et al.  Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  I. Tannock,et al.  Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. , 2012, Urologic oncology.

[3]  Timothy J Wilt,et al.  Radical prostatectomy versus observation for localized prostate cancer. , 2012, The New England journal of medicine.

[4]  F. Saad,et al.  Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial , 2012, The Lancet.

[5]  J. Nelson,et al.  Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration‐resistant nonmetastatic prostate cancer , 2011, Cancer.

[6]  K. Jung,et al.  Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid. , 2011, European urology.

[7]  S. Srivastava,et al.  The Center for Prostate Disease Research (CPDR): a multidisciplinary approach to translational research. , 2009, Urologic oncology.

[8]  Y. Horiguchi,et al.  Prediction of bone metastases by combination of tartrate‐resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer , 2008, International journal of urology : official journal of the Japanese Urological Association.

[9]  S. Loening,et al.  Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression. , 2007, European urology.

[10]  M. Parmar,et al.  Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). , 2007, Journal of the National Cancer Institute.

[11]  C. Tangen,et al.  Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  F. Saad,et al.  Markers of Bone Metabolism and Survival in Men with Hormone-Refractory Metastatic Prostate Cancer , 2006, Clinical Cancer Research.

[13]  Alan W Partin,et al.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. , 2005, JAMA.

[14]  F. Saad,et al.  Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  F. Saad,et al.  Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. , 2005, Journal of the National Cancer Institute.

[16]  S. Loening,et al.  Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: Diagnostic and prognostic implications , 2004, International journal of cancer.

[17]  R. Rizzoli,et al.  Markers of bone turnover for the management of patients with bone metastases from prostate cancer , 2000, British Journal of Cancer.

[18]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[19]  S. S. Brown,et al.  Temporal Changes in the Concentrations of Serum Constituents in Healthy Men , 1979, Annals of clinical biochemistry.

[20]  E. A. Robertson,et al.  Variance components of serum constituents in healthy individuals. , 1978, Clinical chemistry.

[21]  P. Stattin,et al.  Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase. , 2008, The Journal of urology.